



International Journal of Pharmaceuticals and Health care Research (IJPHR)

IJPHR | Vol.13 | Issue 2 | Apr - Jun -2025

www.ijphr.com

DOI : <https://doi.org/10.61096/ijphr.v13.iss2.2025.189-195>

ISSN: 2306-6091

Research

Formulation and Evaluation of Curcuminoids and Flurbiprofen Granules Loaded Capsule and Its *In-Vitro* Anti-Rheumatic Activity

Dr. K. Sivaiah^{1*}, Dr. Archana S. Patil², Dr. Govind Reddy G³, Pooja M Walvekar⁴

¹Associate Professor, Dept. of Pharmacology, TVM College of Pharmacy, Ballari - 583104



²Associate Professor, Dept. of Pharmaceutics, KLE College of Pharmacy, Belagavi - 590010

³Assistant Professor, Dept. of Pharmaceutics, TVM College of Pharmacy, Ballari - 583104

⁴Research Scholar, Dept. of Pharmaceutics, KLE College of Pharmacy, Belagavi – 590010

* Author for Correspondence: Dr. K.Sivaiah

Email: ksiva.pharmacist@gmail.com

| | |
|--|--|
|  | Abstract |
| Published on: 16 Apr 2025 | <p>Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by joint pain, stiffness, and progressive cartilage destruction. The present study aims to formulate and evaluate curcuminoids and flurbiprofen granules loaded capsules for their potential anti-rheumatic activity. Curcuminoids, derived from <i>Curcuma longa</i>, exhibit potent anti-inflammatory and antioxidant properties but suffer from poor bioavailability. Flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), effectively alleviates RA symptoms but is associated with gastrointestinal side effects. To overcome these limitations, this study explores the development of a combination formulation to improve therapeutic efficacy. The granules were prepared using the wet granulation method and encapsulated in hard gelatin capsules. The physicochemical properties of the formulations were assessed, including Fourier Transform Infrared Spectroscopy (FTIR) for compatibility studies, solubility analysis, and in-vitro dissolution studies to determine the drug release profile. The anti-rheumatic potential of the formulation was evaluated using <i>in-vitro</i> models, including free radical scavenging (DPPH assay) and albumin denaturation inhibition assays to assess anti-inflammatory properties. The optimized formulation F4 exhibited significant drug release and anti-rheumatic activity, suggesting its potential as a novel therapeutic approach for RA management.</p> |
| Published by: DrSriram Publications | |
| <p>2025 All rights reserved.</p>  <p>Creative Commons Attribution 4.0 International License.</p> | |
| | <p>Keywords: Curcuminoids, Flurbiprofen, Granules, Capsules, Anti-rheumatic Activity.</p> |

INTRODUCTION

Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects synovial joints, leading to chronic inflammation, pain, and progressive cartilage destruction. It is characterized by immune-mediated damage to synovial tissues, ultimately resulting in joint deformities and disability.^{1,2} Current treatment strategies include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying anti-

rheumatic drugs (DMARDs). However, long-term use of these treatments is associated with significant side effects, including gastrointestinal complications, hepatotoxicity, and cardiovascular risks.^{1,3,4}

Curcuminoids, derived from turmeric (*Curcuma longa*), have been extensively studied for their potent anti-inflammatory, antioxidant, and immunomodulatory properties. Despite their promising therapeutic potential, curcuminoids exhibit poor bioavailability due to rapid metabolism, low water solubility, and limited absorption.⁵ Flurbiprofen, a commonly used NSAID, provides effective pain relief in RA but is associated with gastrointestinal irritation.⁶ Combining curcuminoids with flurbiprofen may enhance anti-rheumatic efficacy while reducing adverse effects.

This study aims to formulate and evaluate granules loaded with curcuminoids and flurbiprofen, encapsulated in hard gelatin capsules, to improve drug solubility, release profile, and therapeutic effectiveness.

MATERIALS AND METHODS

The active pharmaceutical ingredients Curcumin and Piperine were procured from Yucca Enterprises, Mumbai, India, Flurbiprofen was procured from Ulfcar Chemicals Pvt. Ltd. Faridabad, India. To enhance solubility and stability, Beta-cyclodextrin was procured from A B Enterprises, Mumbai and Eudragit L100 from Brisben Chemicals, Mumbai. Additional excipients such as Croscarmellose sodium and Starch were procured from Nice Chemical Pvt. Ltd. Kerala, India along with Lactose from Thermo Fisher Scientific Pvt. Ltd. Bengaluru, India. The analytical and formulation processes utilized high-precision equipment, including a Shimadzu AX200 electronic balance for accurate weighing, a Shimadzu IR Spirit spectrometer for infrared analysis, and a Shimadzu 1800 UV-visible spectrophotometer for spectroscopic evaluation.

Methods

Pre-Formulation Studies

Organoleptic Properties

The physical characteristics such as state, colour, odour, and taste of the raw materials were observed.⁷

Melting Point Determination

The melting point of Curcumin, Piperine, and Flurbiprofen was determined by the capillary tube method using a Thiele tube.⁷

Solubility Studies

The solubility of Curcumin, Piperine, and Flurbiprofen was determined in methanol, distilled water, 0.1N HCl, and PBS 7.4 buffer. Excess drug was added to 10 ml of the solvent, shaken for 15 min, filtered, and analysed spectrophotometrically.^{7,8}

Development of Calibration Curve^{7,8,9,10,11}

The standard calibration curve was constructed using 0.1N HCl and PBS 7.4 buffer. Stock solutions were prepared, and serial dilutions (5-30 µg/mL) were made. Absorbance was recorded at 423.5 nm (Curcuminoids), 342.5 nm (Piperine), and 246 nm (Flurbiprofen).

Drug-excipient compatibility study

FTIR can be used to investigate and predict any physiochemical interaction between different excipient. IR spectra matching approach was used for detection of any possible chemical interaction between the drug and excipient. A physical mixture of drug and excipient were prepared. It was scanned from 4000 to 400 cm⁻¹ in a FTIR spectrophotometer. The IR spectrum of the physical mixture was compared with those of pure drug and physical mixture and peak matching was done to detect any appearance or disappearance of peaks.¹²

Formulation of Granules

Granules containing Curcuminoids, Piperine, and Flurbiprofen were prepared using the wet granulation technique with Beta-cyclodextrin as a complexing agent, Eudragit L100 as a polymer, and Croscarmellose sodium as a super disintegrant.^{13,14} (Table 1)

Table 1: Composition of granules

| Ingredients | Curcuminoid granules | | | |
|-----------------|----------------------|-----------|-----------|-----------|
| | F1 (mg) | F2 (mg) | F3 (mg) | F4 (mg) |
| Curcuminoids | 200 | 200 | 200 | 200 |
| β- cyclodextrin | 200 (1:1) | 200 (1:1) | 400 (1:2) | 400 (1:2) |

| | | | | |
|------------------------------|--------------|--------------|--------------|--------------|
| Piperine | 5 | 5 | 5 | 5 |
| Croscarmellose | 35 (5%) | 70 (10%) | 35 (5%) | 70 (10%) |
| Lactose | 246 | 211 | 46 | 11 |
| Magnesium stearate | 7 | 7 | 7 | 7 |
| Talc | 7 | 7 | 7 | 7 |
| Flurbiprofen granules | | | | |
| Flurbiprofen | 100 | 100 | 100 | 100 |
| Eudragit L100 | 10 (4%) | 15 (6%) | 20 (8%) | 25 (10%) |
| Lactose | 135 | 130 | 125 | 120 |
| Magnesium stearate | 2.5 | 2.5 | 2.5 | 2.5 |
| Talc | 2.5 | 2.5 | 2.5 | 2.5 |
| Total | 950mg | 950mg | 950mg | 950mg |

Post-Formulation Studies

Weight Variation Test

Twenty capsules were randomly selected, and individual weights were compared with the average weight. Capsules were considered acceptable if they contained not less than 95% and not more than 110% of the stated amount of active ingredient.^{8,15}

Drug Content Estimation

Ten capsules were randomly selected. The granules were removed, dissolved in methanol, and diluted to a suitable concentration. The absorbance was measured at respective wavelengths using a UV-visible spectrophotometer.^{8,15}

In-Vitro Dissolution Studies

Dissolution studies were conducted using a USP Type I (Basket type) dissolution apparatus. Capsules were placed in 900 ml of 0.1N HCl (2 hrs) followed by PBS 7.4 pH (10 hrs) at $37 \pm 0.5^\circ\text{C}$ and 50 rpm. Samples were withdrawn at predetermined intervals, filtered, and analyzed at respective wavelengths.¹⁵ (Table 2)

Table 2: Dissolution Parameters

| Parameter | Condition |
|--------------------|---------------------------------------|
| Apparatus | USP Type I (Basket) |
| Dissolution Medium | 0.1N HCl (2 hrs), PBS 7.4 pH (10 hrs) |
| Temperature | $37 \pm 0.5^\circ\text{C}$ |
| Rotation Speed | 50 rpm |
| Sample Volume | 5 mL |

In-Vitro Anti-Rheumatic Activity Studies

DPPH Free Radical Scavenging Assay

The antioxidant activity was determined using the DPPH assay. Different concentrations (50-250 $\mu\text{g/ml}$) of the formulation were incubated with 2.4 ml of DPPH solution and 1.6 ml of ethanol. Absorbance was measured at 517 nm, and percentage scavenging was calculated.^{16, 17}

Equation: DPPH Scavenged (%) = $[(A_0 - A_1)/A_0] \times 100$

Where A_0 = absorbance of control and A_1 = absorbance of test solution.

Albumin Denaturation Method

The anti-inflammatory activity was evaluated by incubating Bovine Serum Albumin (BSA) with the formulation at different concentrations (50-250 $\mu\text{g/ml}$). The solution was heated at 37°C for 15 min, cooled, and absorbance was measured at 660 nm.^{18, 19, 20}

Statistical Analysis

All experiments were performed in triplicate, and results were expressed as mean \pm SD. Statistical significance was determined using one-way ANOVA, with $p < 0.05$ considered significant.

RESULTS AND DISCUSSION

Pre-Formulation Studies

Organoleptic Properties

The organoleptic properties of Curcuminoids, Piperine, and Flurbiprofen were assessed and compared with standard reference values. Curcuminoids appeared as an orange-yellow crystalline powder with an aromatic odour and a bitter taste, whereas Piperine was light green with a pungent odour. Flurbiprofen was a white amorphous powder with a pungent odour. These findings were in agreement with reported literature, confirming the purity and identity of the drugs. (Table 3)

Table 3: Organoleptic Properties of Selected Drugs

| Drug | Appearance | Odour | Taste |
|--------------|----------------------------------|----------|-----------------|
| Curcuminoids | Orange-yellow crystalline powder | Aromatic | Bitter |
| Piperine | Light green crystalline powder | Pungent | Spicy |
| Flurbiprofen | White amorphous powder | Pungent | Slightly bitter |

Melting Point Determination

The melting points of the pure drugs were evaluated to confirm their stability and purity. Curcuminoids, Piperine, and Flurbiprofen exhibited melting points of 183°C, 130°C, and 110°C, respectively, which aligned with standard literature values.(Table 4)

Table 4: Melting Points of Selected Drugs

| Drug | Observed Melting Point (°C) | Standard Melting Point (°C) |
|--------------|-----------------------------|-----------------------------|
| Curcuminoids | 183 | 183 |
| Piperine | 130 | 130 |
| Flurbiprofen | 110 | 110 |

Solubility Studies

The solubility profiles of the three compounds were assessed in different solvents. All three drugs were freely soluble in methanol, sparingly soluble in pH 7.4 PBS, and insoluble in distilled water. This indicates the need for formulation strategies to enhance bioavailability.

Standard calibration curve

The R^2 value of Curcuminoids, piperine and flurbiprofen in 0.1N HCL and PBS 7.4 pH was found to be 0.9984 and 0.9991, 0.9995 and 0.9973, 0.998 and 0.9983 respectively.

FTIR Analysis

In F4 formulation the structural functional groups in the FTIR showed prominent peaks associated with ketone, hydroxy, methoxy, amine and fluorine groups are with the reference IR data. From that results we confirmed that Curcuminoids granules and Flurbiprofen granules are within the IR references data.

In-Vitro Drug Release Studies

The dissolution profiles of Curcuminoids, Piperine, and Flurbiprofen formulations (F1-F4) were assessed using the USP Type I Basket method. (Table 5, Fig 1)

Table 5: Drug Release Profile of Formulations (F1-F4)

| Time (hrs.) | % Cumulative drug release of Flurbiprofen | | | |
|-------------|---|-------|-------|--------|
| | F1 | F2 | F3 | F4 |
| 0 | 0 | 0 | 0 | 0 |
| 3hr | 35.77 | 21.16 | 17.53 | 11.063 |
| 4hr | 47.54 | 30.45 | 25.02 | 18.35 |
| 6hr | 58.81 | 48.68 | 43.61 | 37.27 |
| 8hr | 98.92 | 72.56 | 60.48 | 56.08 |
| 10hr | - | 98.04 | 98.89 | 78.3 |
| 12hr | - | - | - | 99.12 |




Fig 1: In-Vitro Drug Release Profile of (F1-F4)

The cumulative drug release of Flurbiprofen varied across formulations: F1 achieved 98.92% release at 8 hours, F2 and F3 reached 98.89% at 10 hours, and F4 exhibited 98.04% release at 12 hour.

***In-Vitro* Antioxidant Activity**

The antioxidant activity of the formulations was evaluated using the DPPH free radical scavenging assay. (Table 6, 7) (Figure 2).

Table 6: Percentage free radical scavenging activity of DPPH

| Percentage radical scavenge activity (% RSA) | | |
|--|----------|-------|
| Concentration | Standard | F4 |
| 50µg/ml | 14.51 | 4.10 |
| 100µg/ml | 31.23 | 26.18 |
| 150µg/ml | 57.09 | 44.47 |
| 200µg/ml | 76.34 | 60.88 |
| 250µg/ml | 95.26 | 76.02 |

Absorbance of control: 0.317

Table 7: IC₅₀ of standard and F4

| Types | IC ₅₀ |
|----------|------------------|
| Standard | 128.2µg/ml |
| F4 | 153.8µg/ml |




Fig 2: Percentage (%) DPPH scavenging of standard and F4

The *in-vitro* Antioxidant activity along with IC₅₀ is summarized in table No. 6, 7. The percentage inhibition and antioxidant concentration were supported by straight line equation and R² value of F4 and standard. F4 showed percentage inhibition from 4.10 to 76.02 and standard drug presented percentage inhibition from 14.51 to 95.26 at different concentration 50, 100, 150, 200 and 250 µg/ml. The IC₅₀ of F4 and standard was found to be 153.8 µg/ml and 128.2 µg/ml respectively. Lower IC₅₀ value indicates higher antioxidant value. F4 showed moderate antioxidant activity with percentage inhibition of 76.02 at 250 µg/ml when compared to standard with percentage inhibition of 95.26 at 250 µg/ml.

***In-Vitro* Anti-Inflammatory Activity**

The anti-inflammatory potential of the formulations was evaluated using the albumin denaturation method. (Table 8,9) (Figure 3)

Table 8: Percentage inhibition of Albumin denaturation

| Concentration | Percentage inhibition | |
|----------------|-----------------------|-------------|
| | Standard | Formulation |
| 50 µg/ml | 12.5 | 21.45 |
| 100 µg/ml | 27.05 | 36.5 |
| 150 µg/ml | 42.35 | 56.25 |
| 200 µg/ml | 59.64 | 77.12 |
| 250 µg/ml | 75.52 | 93.74 |
| R ² | 0.9974 | 0.998 |

Table 9: IC₅₀ of standard and F4

| Type | IC ₅₀ |
|-----------------------------|------------------|
| Standard | 131.66 µg/ml |
| F4 | 170.28 µg/ml |
| Absorbance of control: 0.08 | |




Fig 3: Percentage inhibition of albumin denaturation of standard and F4

The results indicated that formulation F4 exhibited significant inhibition of protein denaturation (93.74% at 250 µg/ml), compared to the standard (Aspirin) with 75.52% inhibition at the same concentration. The IC₅₀ values for F4 and the standard were found to be 170.28 µg/ml and 131.66 µg/ml, respectively, confirming the potent anti-inflammatory activity of the optimized formulation.

CONCLUSION

The formulated curcuminoids and flurbiprofen granules loaded capsules exhibited promising physicochemical properties, sustained drug release, and potent *in-vitro* anti-rheumatic activity. The combination of curcuminoids with flurbiprofen offers a novel approach to RA management, potentially improving therapeutic outcomes while minimizing adverse effects. Further *in-vivo* studies and clinical trials are warranted to validate these findings and explore their clinical applications.

REFERENCES

1. Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N.J. & Xu, J. (2018) 'Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies', *Bone Research*, 6(1), p. 15.
2. Radu, A.F. & Bungau, S.G. (2021) 'Management of rheumatoid arthritis: an overview', *Cells*, 10(11), p. 2857.
3. Tripathi, K.D. (2013) *Essentials of Medical Pharmacology*. 7th edn. New Delhi: JP Medical Ltd., pp. 192-218.
4. Udayakumar, P. (2007) *Textbook of Pharmacology for Dental and Allied Health Sciences*. 2nd edn. New Delhi: JP Brothers Ltd., pp. 185-189.
5. Sohn, S.I., Priya, A., Balasubramaniam, B., Muthuramalingam, P., Sivasankar, C., Selvaraj, A., Valliammai, A., Jothi, R. & Pandian, S. (2021) 'Biomedical applications and bioavailability of Curcumin - An updated overview', *Pharmaceutics*, 13(12), p. 2102.
6. Brogden, R.N., Heel, R.C., Speight, T.M. & Avery, G.S. (1979) 'Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases', *Drugs*, 18, pp. 417-38.
7. Mahmood, H.S., Ahmed, S., Ullah, M. & Akram, M. (2016) 'Formulation and evaluation of flurbiprofen solid dispersion', *International Journal of Pharmacy and Pharmaceutical Research*, 7(3), pp. 78-90.
8. Bellad, K.A., Kumar, N., Singh, V., Kumar, A., Jain, A. & Bhat, K. (2020) 'Development and evaluation of curcumin floating tablets', *Pharmaceutical Analysis and Acta*, 11.
9. Mir, M.A., Ashraf, M.W. & Mahmud, M. (2020) 'Formulation design and evaluation of solid lipid microparticles of curcumin for the treatment of Alzheimer's disease', *International Journal of Research in Pharmaceutical Sciences*, 11(4).
10. Ziani, N. & Mouas, T.N. (2021) 'Efficient extraction and structural analysis of biosourced piperine as natural adjuvant', *Proceedings of the 1st International Electronic Conference on Agronomy*, 3(13).
11. Wdowiak, K., Kowalczyk, A., Puk, K., Wróblewska, A., Sztanke, M., Celejewski, M., Józwiak, K. & Sztanke, K. (2023) 'Amorphous system of hesperetin and piperine: Improvement of apparent solubility, permeability, and biological activities', *International Journal of Molecular Sciences*, 24(5).
12. Kamble, R.S., Jadhav, R.T., Deshmukh, T.A. & Jadhav, S.L. (2010) 'Formulation and development of enteric coated dosage form using ketorolac tromethamine', *International Journal of Pharmaceutical Research and Development*, 2(8), pp. 126-35.
13. Dua, K., Ramana, M.V., Sara, U.V.S., Himaja, M., Agrawal, A.K. & Garg, V. (2011) 'Enhancement of dissolution behavior of aceclofenac by complexation with β -cyclodextrin-choline dichloride coprecipitate', *Journal of Dispersion Science and Technology*, 32(10), pp. 1477-84.
14. Nagra, U., Naz, S., Iqbal, J. & Raza, S.A. (2019) 'Effect of sustained release polymers on drug release profile of aceclofenac tablets: Physicochemical properties, analysis of kinetics, and fit factor', *Indian Journal of Pharmaceutical Education and Research*, 53, pp. 58-65.
15. Hadi, M.A., Patel, B., Singhal, M., Pund, S. & Bairagi, R. (2012) 'Formulation and evaluation of enteric coated sustained release tablets of flurbiprofen for chronotherapeutic treatment of rheumatoid arthritis', *Journal of Pharmaceutical Research*, 5(11), pp. 5093-98.
16. Sadeghi, Z., Valizadeh, J. & Shermeh, O.A. (2015) 'Antioxidant activity and total phenolic contents of some date varieties from Saravan Region, Baluchistan, Iran', *Journal of Medicinal Plants Research*, 9(4), pp. 78-83.
17. Mensor, L.L., Menezes, F.S., Leitão, G.G., Reis, A.S., Santos, T.C., Coube, C.S. & Leitão, S.G. (2001) 'Screening of Brazilian plant extracts for antioxidant activity by the use of DPPH free radical method', *Phytotherapy Research*, 15(2), pp. 127-30.
18. Sridevi, G., Sembulingam, P., Sembulingam, K., Srividya, S. & Ibrahim, M. (2015) 'Evaluation of in-vitro anti-inflammatory activity of Pergularia daemia', *World Journal of Pharmaceutical Research*, 4(8), pp. 1747-56.
19. Sakat, S., Juvekar, A.R. & Gambhire, M.N. (2010) 'In-vitro antioxidant and anti-inflammatory activity of methanol extract of *Oxalis corniculata* Linn', *International Journal of Pharmaceutical Sciences*, 2(1), pp. 146-55.
20. Ruiz-Ruiz, J.C., Matus-Basto, A.J., Acereto-Escoffie, P. & Segura-Campos, M.R. (2017) 'Antioxidant and anti-inflammatory activities of phenolic compounds isolated from *Melipona beecheii* honey', *Food and Agricultural Immunology*, 28(6), pp. 1424-37.